[
  {
    "ts": null,
    "headline": "AMGEN ANNOUNCES SENIOR EXECUTIVE RESEARCH APPOINTMENT",
    "summary": "Amgen (NASDAQ:AMGN) today announced that Howard Chang, M.D., Ph.D., will join the company as senior vice president of Research, effective Dec. 16, 2024. Chang will also assume the title and responsibility of serving as Amgen's chief scientific officer, reporting to Jay Bradner, M.D., executive vice president of Research and Development.",
    "url": "https://finnhub.io/api/news?id=5ba214f290a80cc41bff5b0a8ce7e7518338ab26057506fb569423ab653fc18a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732136400,
      "headline": "AMGEN ANNOUNCES SENIOR EXECUTIVE RESEARCH APPOINTMENT",
      "id": 131523808,
      "image": "https://media.zenfs.com/en/prnewswire.com/2c1a06bdf6720fdfc4a33394e07a9a88",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Amgen (NASDAQ:AMGN) today announced that Howard Chang, M.D., Ph.D., will join the company as senior vice president of Research, effective Dec. 16, 2024. Chang will also assume the title and responsibility of serving as Amgen's chief scientific officer, reporting to Jay Bradner, M.D., executive vice president of Research and Development.",
      "url": "https://finnhub.io/api/news?id=5ba214f290a80cc41bff5b0a8ce7e7518338ab26057506fb569423ab653fc18a"
    }
  },
  {
    "ts": null,
    "headline": "Amgen Names Howard Chang as Chief Scientific Officer",
    "summary": "By Stephen Nakrosis Amgen on Wednesday said Howard Chang will join the company as senior vice president of research, effective Dec. 16. The company said Chang, who will also serve as chief...",
    "url": "https://finnhub.io/api/news?id=dd4790754d6bcdba04cc9571a66eb53182506d1ed42d99dff08e6149c2a648df",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732120751,
      "headline": "Amgen Names Howard Chang as Chief Scientific Officer",
      "id": 131519146,
      "image": "",
      "related": "AMGN",
      "source": "Finnhub",
      "summary": "By Stephen Nakrosis Amgen on Wednesday said Howard Chang will join the company as senior vice president of research, effective Dec. 16. The company said Chang, who will also serve as chief...",
      "url": "https://finnhub.io/api/news?id=dd4790754d6bcdba04cc9571a66eb53182506d1ed42d99dff08e6149c2a648df"
    }
  },
  {
    "ts": null,
    "headline": "Amgen Inc. stock outperforms competitors on strong trading day",
    "summary": "Amgen Inc. stock outperforms competitors on strong trading day",
    "url": "https://finnhub.io/api/news?id=18a5e7c8d242be3a7e8a20536693af3f14f1796686540040396c682c7c78706d",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732120740,
      "headline": "Amgen Inc. stock outperforms competitors on strong trading day",
      "id": 131530577,
      "image": "",
      "related": "AMGN",
      "source": "MarketWatch",
      "summary": "Amgen Inc. stock outperforms competitors on strong trading day",
      "url": "https://finnhub.io/api/news?id=18a5e7c8d242be3a7e8a20536693af3f14f1796686540040396c682c7c78706d"
    }
  },
  {
    "ts": null,
    "headline": "SLN Stock Down Despite Cholesterol Drug Lowering Lipoprotein Levels",
    "summary": "Silence Therapeutics stock falls despite lowering lipoprotein levels in a phase II study of zerlasiran likely due to concerns regarding its competitive profile.",
    "url": "https://finnhub.io/api/news?id=162765637977070343d1ee1c372b67296262a8101146c361e46a9a2cc37df8f6",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732118640,
      "headline": "SLN Stock Down Despite Cholesterol Drug Lowering Lipoprotein Levels",
      "id": 131514663,
      "image": "https://media.zenfs.com/en/zacks.com/048cb98376b33bd6dcff462577373727",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Silence Therapeutics stock falls despite lowering lipoprotein levels in a phase II study of zerlasiran likely due to concerns regarding its competitive profile.",
      "url": "https://finnhub.io/api/news?id=162765637977070343d1ee1c372b67296262a8101146c361e46a9a2cc37df8f6"
    }
  },
  {
    "ts": null,
    "headline": "UnitedHealth, Amgen share gains lead Dow's 114-point climb",
    "summary": "UnitedHealth, Amgen share gains lead Dow's 114-point climb",
    "url": "https://finnhub.io/api/news?id=895ac2253a74c3695cc02979632c86338e6e57c4894ebc96aa7456e83c84c532",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732116900,
      "headline": "UnitedHealth, Amgen share gains lead Dow's 114-point climb",
      "id": 131528387,
      "image": "",
      "related": "AMGN",
      "source": "MarketWatch",
      "summary": "UnitedHealth, Amgen share gains lead Dow's 114-point climb",
      "url": "https://finnhub.io/api/news?id=895ac2253a74c3695cc02979632c86338e6e57c4894ebc96aa7456e83c84c532"
    }
  },
  {
    "ts": null,
    "headline": "XLV: Healthcare Stocks In Critical Condition (Rating Downgrade)",
    "summary": "We advise selling healthcare stocks due to political uncertainty and unfavorable market conditions, prioritizing low-risk investments. See more on XLV ETF here.",
    "url": "https://finnhub.io/api/news?id=fda1041225add2352abc51ab2126c9563bd38831235bdf55044cf40be42ddef3",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732093680,
      "headline": "XLV: Healthcare Stocks In Critical Condition (Rating Downgrade)",
      "id": 131502070,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1496411389/image_1496411389.jpg?io=getty-c-w1536",
      "related": "AMGN",
      "source": "SeekingAlpha",
      "summary": "We advise selling healthcare stocks due to political uncertainty and unfavorable market conditions, prioritizing low-risk investments. See more on XLV ETF here.",
      "url": "https://finnhub.io/api/news?id=fda1041225add2352abc51ab2126c9563bd38831235bdf55044cf40be42ddef3"
    }
  }
]